Sign Up Now to Download a Free Research Report on BIIB
Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts
Having problems viewing PDF files? Biogen Idec Inc.
Biogen Idec shares spiked approximately 3.5 percent on volume of over 1.0 million shares traded Monday. The company announced that the FDA has started its review of Biogen’s hemophilia A treatment. Biogen’s hemophilia B treatment, Alprolix, review began in March.
Going forward ... (see research report)
Subscribe to News Feeds